MARAVIROC Drug Patent Profile
✉ Email this page to a colleague
When do Maraviroc patents expire, and when can generic versions of Maraviroc launch?
Maraviroc is a drug marketed by Hetero Labs Ltd Iii and I 3 Pharms and is included in two NDAs.
The generic ingredient in MARAVIROC is maraviroc. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the maraviroc profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Maraviroc
A generic version of MARAVIROC was approved as maraviroc by HETERO LABS LTD III on February 7th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MARAVIROC?
- What are the global sales for MARAVIROC?
- What is Average Wholesale Price for MARAVIROC?
Summary for MARAVIROC
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 91 |
| Clinical Trials: | 140 |
| Patent Applications: | 5,576 |
| Drug Prices: | Drug price information for MARAVIROC |
| DailyMed Link: | MARAVIROC at DailyMed |
Recent Clinical Trials for MARAVIROC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Orlando Immunology Center | Phase 4 |
| Hospital General de México Dr. Eduardo Liceaga | Phase 2 |
Pharmacology for MARAVIROC
| Drug Class | CCR5 Co-receptor Antagonist |
| Mechanism of Action | Chemokine Co-receptor 5 Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for MARAVIROC
US Patents and Regulatory Information for MARAVIROC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hetero Labs Ltd Iii | MARAVIROC | maraviroc | TABLET;ORAL | 203347-001 | Feb 7, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| I 3 Pharms | MARAVIROC | maraviroc | TABLET;ORAL | 217114-002 | Aug 17, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hetero Labs Ltd Iii | MARAVIROC | maraviroc | TABLET;ORAL | 203347-002 | Feb 7, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| I 3 Pharms | MARAVIROC | maraviroc | TABLET;ORAL | 217114-001 | Aug 17, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MARAVIROC
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| ViiV Healthcare B.V. | Celsentri | maraviroc | EMEA/H/C/000811 Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable, |
Authorised | no | no | no | 2007-09-18 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
